Ahmed Abdalbagi – Drug Interactions Every Healthcare Professional Must Know
Ahmed Abdalbagi, Pharmacist at Pharma Trading Co.Ltd., posted on LinkedIn:
”CRITICAL ALERT: Drug Interactions Every Healthcare Professional Must Know
Patient safety hinges on our vigilance. As medication experts, pharmacists play a pivotal role in intercepting dangerous drug interactions that can lead to hospitalizations, permanent harm, or worse.
Here are clinically significant interactions, updated with current guidelines, that demand our immediate attention:
Sildenafil (and all PDE5 inhibitors) + Organic Nitrates (Nitroglycerin)
Risk: Profound, refractory hypotension. This is an absolute contraindication. Life-threatening.
Clopidogrel + Omeprazole/Esomeprazole
Risk: Significant reduction in Clopidogrel’s antiplatelet effect due to CYP2C19 inhibition. Increases risk of stent thrombosis and cardiovascular events. Use Pantoprazole or Rabeprazole if PPI is essential.
Warfarin + NSAIDs or Metronidazole
Risk: Potentiated anticoagulation and synergistic GI irritation. High risk of major bleeding. Monitor INR closely; recommend paracetamol for pain.
Potassium-Sparing Diuretics+ ACEi/ARB (Captopril, Lisinopril)
Risk: Severe hyperkalemia. Mandatory potassium monitoring is required, especially in patients with renal impairment or diabetes.
Gentamicin + Loop Diuretics (Furosemide)
Risk: Additive ototoxicity. Permanent hearing damage can occur. Closely monitor renal function and avoid concurrent use when possible.
SSRIs+ NSAIDs/Aspirin
Risk: Significantly increased risk of upper GI bleeding. The combination requires gastroprotection with a PPI.
Ondansetron + Tramadol
Risk: Ondansetron can blunt the analgesic effect of Tramadol by inhibiting its activation via CYP2D6. Consider alternative antiemetics like Metoclopramide.
QTc-Prolonging Agents: Fluoroquinolones (Levofloxacin) + Macrolides (Clarithromycin) + Antipsychotics
Risk: Additive QTc prolongation, potentially leading to Torsades de Pointes. A critical consideration in polypharmacy patients.
Statins (Simvastatin, Atorvastatin) + CYP3A4 Inhibitors (Clarithromycin, Fluconazole)
Risk: Dramatically increased statin levels, leading to rhabdomyolysis and acute kidney injury.
Digoxin + Amiodarone / Clarithromycin / Verapamil
Risk: These drugs increase Digoxin serum concentrations, leading to Digoxin toxicity (nausea, bradycardia, arrhythmias). Dose reduction and close monitoring are essential.
Why This Matters:
Polypharmacy is on the rise. In our collaborative practice, a single alert from a pharmacist can be the line of defense against a preventable adverse drug event (ADE). Medication safety is a non- negotiable team sport.
What is the most critical drug interaction you’ve intervened on recently? Share your experience to elevate our collective practice.”
Stay informed with Hemostasis Today.
-
Sep 3, 2026, 11:21Thrombotic Microangiopathies: From Clinical Syndrome to Molecularly Targeted Therapy
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease